KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EPS (Basic) for 16 consecutive years, with $0.84 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 229.23% year-over-year to $0.84, compared with a TTM value of $2.39 through Dec 2025, up 209.63%, and an annual FY2025 reading of $2.39, up 209.63% over the prior year.
  • EPS (Basic) was $0.84 for Q4 2025 at Alnylam Pharmaceuticals, down from $2.25 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.25 in Q3 2025 and bottomed at -$3.32 in Q3 2022.
  • Average EPS (Basic) over 5 years is -$0.99, with a median of -$1.25 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 358.62% in 2025, while the deepest fall reached 300.0% in 2025.
  • Year by year, EPS (Basic) stood at -$2.16 in 2021, then increased by 21.76% to -$1.69 in 2022, then skyrocketed by 35.5% to -$1.09 in 2023, then surged by 40.37% to -$0.65 in 2024, then surged by 229.23% to $0.84 in 2025.
  • Business Quant data shows EPS (Basic) for ALNY at $0.84 in Q4 2025, $2.25 in Q3 2025, and -$0.56 in Q2 2025.